enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman

enVVeno Medical (NASDAQ:NVNO) released the third episode of its investor video series, "WTF with Rob Berman," featuring its CEO.

Rhea-AI Summary

enVVeno Medical (NASDAQ:NVNO) released the third episode of its investor video series, "WTF with Rob Berman," featuring its CEO.

The episode discusses the total addressable market—the potential market size—for severe deep venous insufficiency (DVI). Berman covers the patient population, the market opportunity and what he describes as investors' frequent misunderstandings about market size. The announcement provides no patient-population figures or clinical results.

Key Terms

total addressable market, deep venous insufficiency

2 terms

total addressable market financial

"breaks down the total addressable market (TAM) for severe deep venous insufficiency"

Total addressable market is the total potential sales opportunity for a product or service if it were to reach every possible customer. It helps investors understand the maximum size of the market and the growth potential for a business. Think of it as the entire pie available to be shared, indicating how big the opportunity could be.

deep venous insufficiency medical

"for severe deep venous insufficiency (DVI), a condition with significant unmet need"

Deep venous insufficiency is a condition where the one-way valves in the deep veins of the legs fail, letting blood pool or flow backward instead of returning efficiently to the heart — imagine valves in a pipe that no longer close properly. For investors, it matters because it drives demand for treatments, diagnostic tests and medical devices, influences healthcare spending and reimbursement trends, and can affect the commercial prospects and regulatory risk for companies developing related therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, CA / ACCESS Newswire / October 21, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced the release of the third episode of its video series, "WTF with Rob Berman". The series gives investors real answers to what they need to know about enVVeno medical and why they need to know it.

In the new episode, Rob Berman, CEO of enVVeno Medical, breaks down the total addressable market (TAM) for severe deep venous insufficiency (DVI), a condition with significant unmet need and few effective treatment options. He walks through the size of the patient population, what it means for the market opportunity, and what investors frequently misunderstand about TAM.

Watch the next episode of WTF with Rob Berman here.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

INVESTOR CONTACT:

JTC Team, LLC
Jenene Thomas
NVNO@jtcir.com
(908) 824-0775

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire